Vaccine Immunity in Children After Hematologic Cancer Treatment: A Retrospective Single-center Study.
Melissa CetinFabienne Gumy-PauseRenato GualtieriKlara M Posfay-BarbeGeraldine Blanchard-RohnerPublished in: Journal of pediatric hematology/oncology (2023)
An effective individualized vaccination program post-cancer based on serology results should be accompanied by an appropriate serology tracking method and follow-up to assess if booster doses are necessary. Our study supports vaccinating all children with a dose of the 13-valent pneumococcal conjugate at cancer diagnosis and at 3 months post-treatment with the combined diphtheria-tetanus-acellular pertussis/poliomyelitis vaccine/hepatitis B virus plus or minus Hib and 13-valent pneumococcal conjugate and meningococcal vaccine, including measles/mumps/rubella-varicella zoster virus vaccine if good immune reconstitution is present.